The company is voluntarily recalling product because of glass particles found in vials.
On Jan. 3, 2018, AuroMedics Pharma LLC announced it was voluntarily recalling lot AFO l 17001-A of Ampicillin and Sulbactam for Injection USP, 1.5 g (equivalent to 1 g ampicillin as the sodium salt plus 0.5 g Sulbactam as the sodium salt) in a Single-Dose vial, to the hospital level. The product is being recalled after glass particulates were found in vials.
According to the company, if glass is present in the intravenous drug and is administered, reactions from local irritation and swelling to more serious conditions such as blockage and clotting in blood vessels may occur. No adverse events have been reported as of January 3.
The affected lot has an expiration date of December 2018 and is packaged in a carton containing 10 vials, NDC: 55150-116-20. The lot was shipped to wholesalers and/or hospitals nationwide on Feb. 9, 2017.
Ampicillin and Sulbactam for Injection is used to treat infections “due to susceptible strains of designated microorganism in skin and skin structure infections, intraÂabdominal infections, and gynecological infections in adults and for treatment of skin and skin structure infection in pediatric patient one year and older,” according to a press release.
Source: FDA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.